Shingles Vaccination Linked to Reduced Risk of Heart Attack and Stroke: A Comprehensive Meta-Analysis

A recent comprehensive review and meta-analysis has revealed a significant association between herpes zoster (shingles) vaccination and a lower incidence of cardiovascular events, including heart attacks and strokes. This groundbreaking research consolidates data from multiple studies worldwide, providing new insights into the potential additional benefits of shingles vaccination.

The study, the first of its kind to globally assess the relationship between herpes zoster vaccination and cardiovascular risk, was presented at the 2025 European Society of Cardiology Congress in Madrid. It evaluated data from 19 studies, including eight observational analyses and one randomized controlled trial, focusing on the effect of herpes zoster vaccines—either the recombinant herpes zoster vaccine (RZV) or the live attenuated zoster vaccine (ZVL)—on cardiovascular health.

Findings indicated that adults aged 18 and older who received the shingles vaccine experienced an 18% reduction in heart attack and stroke risk. Specifically, vaccinated individuals showed a 16% risk reduction compared to unvaccinated groups. The absolute risk difference ranged from 1.2 to 2.2 fewer cardiovascular events per 1,000 person-years, highlighting the potential public health impact.

The analysis also noted that the association persisted across different age groups, including those 50 years or older. Despite these promising results, the authors emphasized that most evidence stems from observational studies, which are prone to bias and do not establish causality. They highlighted the necessity for further research, such as randomized controlled trials, to confirm these findings.

Herpes zoster, caused by reactivation of the varicella-zoster virus, is well-known for producing shingles. However, it can also invade blood vessels, leading to inflammation and vascular remodeling, which may contribute to stroke and other cardiovascular complications. Previous studies suggested a transient increase in cardiovascular risk following shingles outbreaks, but the protective role of vaccination remains under investigation.

While the findings are encouraging, experts recommend additional research to clarify whether vaccines directly contribute to cardiovascular protection or if other factors are at play. Patients are advised to continue following existing vaccination guidelines and consult healthcare providers for personalized advice.

This new evidence underscores the importance of herpes zoster vaccination, not only for preventing shingles but potentially also for reducing the burden of cardiovascular disease—an insight that could influence future vaccine policies and strategies for cardiovascular risk management.